Cessatech reports Regulatory Green Light for trial 0205, the pivotal trial for CT001 - first patient expected shortly
· Trial 0205, the pivotal trial, will investigate the postoperative analgesic efficacy of CT001, in adult participants following impacted mandibular third molar extraction, a randomised, double-blind placebo controlled trial with 220 patients. · Regulatory green light and approval is finally in place, a process that has taken much too long by the authorities. · Patient recruitment will be initiated very soon, and we anticipate to finalise recruitment by early 2022.Cessatech A/S announces that the pivotal trial 0205 has obtained regulatory approval and thereby green light by the